| ²é¿´: 1082 | »Ø¸´: 2 | |||
LCqingboгæ (СÓÐÃûÆø)
|
[½»Á÷]
IND£¨ÐÂÒ©ÁÙ´²Ñо¿)£¬ÓÐÒ»¶ÎÓ¢ÎÄ˵Ã÷£¬²»Àí½âɶÒâ˼ ÒÑÓÐ1È˲ÎÓë
|
|
Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
» ²ÂÄãϲ»¶
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
105500ҩѧµ÷¼Á£¬Ò»Ö¾Ô¸¶¥9£¬Ö÷³ÖÊ¡¼¶´ó´´£¬ÊµÑéÐÍSCI¶þ×÷£¬ËÄÁù¼¶Òѹý£¬Ë«¹ú½±
ÒѾÓÐ6È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ105È˻ظ´
ҩѧר˶µ÷¼Á
ÒѾÓÐ0È˻ظ´
publcifµÄʹÓÃ
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
»á¼Æ×¨Ë¶Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
ÒѾÓÐ14È˻ظ´
Çë½Ìõ£°·ËõºÏ·´Ó¦
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸´óÁ¬Àí¹¤ÖÆÒ©¹¤³Ìר˶086002£¬±¾¿Æ211£¬×Ü·Ö342
ÒѾÓÐ0È˻ظ´
lyblyb1212
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 21
- ºì»¨: 2
- Ìû×Ó: 10
- ÔÚÏß: 6.7Сʱ
- ³æºÅ: 1836701
- ×¢²á: 2012-05-27
- ÐÔ±ð: GG
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
|
ÔÎÄ£ºCurrent Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. ·Ò룺ÏÖÐеÄÁª°î·¨Âɹ涨£¬ÔÚÒ©Æ·ÔËÊä»ò·Ö·¢µ½¸÷ÖÝǰ£¬Ò©Æ·Ó¦µ±¾Åú×¼ÔÊÐíÉÏÊС£ ÓÉÓÚÉê°ìÕß¿ÉÄÜÏ뽫Ñо¿ÓÃÒ©ÎïÔËË͵½¸÷ÖݵÄÁÙ´²Ñо¿Õߣ¬Òò´Ë±ØÐëѰÇó»íÃâ¸Ã·¨ÂÉÒªÇó¡£ IND¾ÍÊÇÉê°ìÕß´Ó¼¼ÊõÉÏ»ñµÃFDA»íÃâµÄÊֶΡ£ |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
2Â¥2017-12-28 16:44:32
LCqingbo
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 812.8
- Ìû×Ó: 66
- ÔÚÏß: 5.8Сʱ
- ³æºÅ: 7498381
- ×¢²á: 2017-11-20
- רҵ: ºÏ³ÉÒ©Îﻯѧ
3Â¥2017-12-28 17:45:12













»Ø¸´´ËÂ¥
LCqingbo